SCHEMBL20135002

SCHEMBL20135002

Cc1cnc(N2CCNC(C)C2)c(C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 1/20 0.43
HRH4 Q9H3N8 2/20 0.42
PIM1 P11309 1/20 0.39
PIM3 Q86V86 1/20 0.39
PIM2 Q9P1W9 1/20 0.39
KHK P50053 1/20 0.38
PRKCQ Q04759 2/20 0.38
PRKCD Q05655 1/20 0.38
MAPK13 O15264 1/20 0.37
MAPK12 P53778 1/20 0.37
MAPK11 Q15759 1/20 0.37
MAPK14 Q16539 1/20 0.37
ACVR1 Q04771 1/20 0.37
BCL2A1 Q16548 2/20 0.36
ROCK2 O75116 2/20 0.36
ROCK1 Q13464 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
PRKCI P41743 1/20 0.35
CHRM2 P08172 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20134990 1.00 KIT (0.43) KITHRH4PIM1PIM3PIM2
SCHEMBL29688471 1.00 KIT (0.43) KITHRH4PIM1PIM3PIM2
SCHEMBL20135325 1.00 KIT (0.43) KITHRH4PIM1PIM3PIM2
Hydrochloric Acid SCHEMBL29688550 0.98 KIT (0.42) KITHRH4PIM1PIM3PIM2
SCHEMBL907486 0.85 KIT (0.41) KITHRH4PIM1PIM3PIM2
SCHEMBL907485 0.85 KIT (0.41) KITHRH4PIM1PIM3PIM2
SCHEMBL20135461 0.83 PRKCQ (0.43) PIM1PIM3PIM2PRKCQPRKCD
SCHEMBL20135462 0.83 PRKCQ (0.43) PIM1PIM3PIM2PRKCQPRKCD
SCHEMBL4920049 0.81 HDAC1 (0.42) KITHRH4PIM1PIM3PIM2
SCHEMBL4920051 0.81 HDAC1 (0.42) KITHRH4PIM1PIM3PIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 KIT 3435/4885HRH4 1220/4885PIM1 2924/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 KIT 3146/4885HRH4 1475/4885PIM1 2728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.